Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study

• Published in: Advances in therapy 2022-02, Vol.39 (2), p.1068-1080
• Main Authors: Ghislain, Pierre-Dominique, Lambert, Jo, Lam Hoai, X. L., Hillary, Tom, Roquet-Gravy, Pierre-Paul, de la Brassinne, Michel, Segaert, Siegfried
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Belgium; Cardiology; Endocrinology; Humans; Internal Medicine; Medicine; Medicine & Public Health; NCT; NCT03097003; Oncology; Original Research; Pharmacology/Toxicology; Psoriasis - drug therapy; Quality of Life; Rheumatology; Severity of Illness Index; Thalidomide - analogs & derivatives; Treatment Outcome
• ISSN: 0741-238X; 1865-8652; 1865-8652
• DOI: 10.1007/s12325-021-01981-7

Introduction Apremilast is approved for the treatment of psoriasis and psoriatic arthritis. However, data on the efficacy and safety of apremilast in clinical practice are limited. We assessed the real-world use and effectiveness of apremilast in patients with moderate to severe plaque psoriasis visiting dermatologist practices in Belgium, from the perspectives of the patient and the physician. Methods This prospective observational study enrolled adults aged 18 years or more initiating apremilast between 6 April 2017 and 30 June 2018, per Belgian reimbursement criteria. Primary outcome was the Patient Benefit Index for Skin Diseases (PBI-S). Secondary outcomes included the Patient Global Assessment (PtGA), Dermatology Life Quality Index (DLQI), Psoriasis Area and Severity Index (PASI), and body surface area (BSA). Patients were followed up for up to 18 months. Results Overall, 122 enrolled patients received at least one dose of apremilast, of which 89 received treatment for more than 150 days and were included in the reference population. Treatment goals most frequently identified (at least 70% of patients) as “very important” in the PBI-S were related to physical impairments. After 6 months of apremilast treatment, 61–78% of patients reported they had achieved these goals; only 12.5% assessed their disease as severe (PtGA, 53.6% at apremilast initiation) and over half reported a DLQI score of 5 or less, indicating improved quality of life. As assessed by the physician, 68.4% and 35.1% of patients achieved at least a 50% and 75% reduction in PASI, respectively, at month 6. Apremilast was well tolerated with no new safety signals identified. Conclusions Our real-world data indicate that apremilast fulfils the expectations of Belgian patients with moderate to severe psoriasis, and from the perspectives of both the patient and physician, apremilast has a positive impact on their disease. Trial Registration ClinicalTrials.gov Identifier NCT03097003.